Sarepta Therapeutics moved to reshape expectations for its Elevidys clinical timeline, disputing the pace laid out for its non-ambulatory study readout. The company said it is delaying the release of 12-week data, after previously signaling an end-of-year update. At the same time, STAT’s reporting highlighted fresh safety and transparency concerns around gene editing in China, including a renewed debate after a child died in a CRISPR gene editing trial. The developments add urgency for companies balancing regulatory navigation with patient safety reporting as gene editing continues to expand. Together, the updates show how both conventional gene therapy timelines and cutting-edge genome editing trials are under intensified scrutiny from investors and regulators alike—where missing endpoints or unclear data rollouts can directly shift trial strategy and funding perception.